Why It Matters
Prescription drug affordability remains one of the most politically resonant issues in the United States, with a majority of Americans expressing concern about their ability to pay for medications. Translating President Trump’s executive push on drug pricing into durable policy will require bipartisan congressional support — making Democratic buy-in a critical variable.
What Happened
Sen. Peter Welch (D-Vt.) said Wednesday he would support President Trump’s most favored nation drug pricing initiative, going further than a simple endorsement. Welch said he would “not only vote for it, I would work actively and aggressively to make it happen,” according to remarks delivered at a health policy summit.
Welch also pushed back on the pace of the administration’s effort, noting that Trump has yet to introduce formal legislation. He urged the president to follow through rather than limit the proposal to public statements.
The Bipartisan Bill Already in Play
Welch is not waiting on the White House. He and Sen. Josh Hawley (R-Mo.) have been developing a joint bill that would prohibit pharmaceutical manufacturers from charging American consumers more than the average price paid in other developed countries. When Welch introduced the measure in early May, he described it as a congressional framework the Trump administration could use to formalize its drug-pricing goals.
Trump’s most favored nation approach is designed to align U.S. drug prices with lower rates paid by peer nations. The administration has reached non-public agreements with at least 16 pharmaceutical companies under this framework, though the undisclosed terms have drawn scrutiny from some Democrats who question whether the deals favor industry over consumers.
By the Numbers
- 16+ pharmaceutical companies have reached agreements with the Trump administration under the most favored nation framework
- Majority of Americans report being at least somewhat concerned about prescription drug affordability
- More than a quarter of Americans say they trust neither party to address high drug costs, per KFF health research
- Polling shows Democrats hold a trust advantage over Republicans on drug pricing, though the gap is narrowing
Zoom Out
The drug pricing debate intersects with a broader set of healthcare pressures currently moving through Washington. Wholesale inflation jumped 6% in April on an annual basis, the steepest increase since 2022, adding economic urgency to consumer cost concerns across healthcare and other sectors.
Welch also addressed the Democratic Party’s broader healthcare agenda, noting that rural health clinics are closing in anticipation of Medicaid reductions tied to the administration’s tax legislation. He said extending Affordable Care Act premium subsidies would be a top Democratic priority if the party regains a Senate majority following November elections.
What’s Next
Congressional action on most favored nation drug pricing depends on whether the White House sends formal legislation to Capitol Hill. The Welch-Hawley bill offers one potential vehicle, though it would need to advance through committee and attract broader support in both chambers. The administration’s private agreements with pharmaceutical companies will also face continued scrutiny as long as their terms remain undisclosed. The Senate recently confirmed a new Fed chair, signaling continued movement on major economic policy fronts where bipartisan coalitions are proving possible.